Cidariini

 Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease

Retrieved on: 
Monday, May 15, 2023
Neurology, Biotechnology, Pharmaceutical, Optical, Health, Infectious Diseases, Clinical Trials, Other Health, Alzheimer's disease, Marketing, DDF, Business, Janssen, MBA, Retina, Vanderbilt University, Genentech, Eli Lilly, Venture, Forma, Acquisition, Novartis, Fibrin, Patient, Engineering, Coagulation, Novo Nordisk, Growth, Immunology, Therapy, Chemical engineering, Infection, Safety, Roche, Pharmaceutical industry, Cidariini, Ophthalmology

“Initiating first-in-human dosing for THN391 is a significant milestone and we’re excited about the approach that Therini Bio is taking towards treating Alzheimer’s disease and other inflammatory neurodegenerative and retinal diseases.

Key Points: 
  • “Initiating first-in-human dosing for THN391 is a significant milestone and we’re excited about the approach that Therini Bio is taking towards treating Alzheimer’s disease and other inflammatory neurodegenerative and retinal diseases.
  • "We are thrilled to announce the initiation of first-in-human dosing for THN391, our fibrin-targeting therapeutic candidate for Alzheimer's disease.
  • “I look forward to working alongside the Therini Bio team to help advance this candidate and its pipeline of fibrin-targeted therapeutic candidates.
  • We are thrilled to have Frank join Therini Bio as Executive Chairperson of the Board, as Therini Bio advances their fibrin-targeting therapeutic candidate for Alzheimer's disease and retinal diseases.

Adimab Provides 2021 Update on Clinical Pipeline

Retrieved on: 
Wednesday, January 19, 2022
Health, Clinical Trials, Regeneron Pharmaceuticals, Acceleron, Human, Nextpoint, Monoclonal antibody, Biotechnology, Antibody, BLA, Lilly, Sanofi, Philosophy, Sintilimab, Novartis, Partner, Merck, Boehringer Ingelheim, Biogen, GSK, Therapy, Mapp Biopharmaceutical, Mouse, CD3, Bristol Myers Squibb, FDA, Engineering, LLC, Top of the Form (quiz show), Novo Nordisk, Fine chemical, Pharmaceutical industry, Cidariini, Cultural icon, Takeda, Biotechnology Innovation Organization, Fourth, fifth, and sixth derivatives of position

In 2021, Innovent and Lilly filed a BLA with the FDA for approval in the United States.

Key Points: 
  • In 2021, Innovent and Lilly filed a BLA with the FDA for approval in the United States.
  • In 2021, Adimab partners exercised 10 commercial licenses to advance programs into development, bringing the total number of optioned programs to more than 85.
  • Adimab focuses solely on its partners and not on developing an internal product pipeline.
  • Since 2009, Adimab has partnered with 95 pharmaceutical and biotechnology companies, generating 425 therapeutic programs, 55 clinical programs, and its first approved product.